Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Child developmental issues news

Show

From To
No evidence that contaminated nelfinavir led to increased risk of birth abnormalities or cancer

HIV-negative infants potentially exposed in utero to doses of the HIV protease inhibitor nelfinavir (Viracept) contaminated with the toxic compound ethyl methyl sulfone (EMS) did not have an

Published
10 October 2016
By
Michael Carter
People shifting from paediatric to adult HIV care have a high risk of ART failure

HIV-positive adolescents and young adults are especially likely to experience the virological failure of their antiretroviral treatment when they move from paediatric to adult HIV care, according to

Published
09 August 2016
By
Michael Carter
HIV—Pregnancy-related issues

Themed issue of CATIE's magazine Treatment Update, with several articles on the safety of antiretrovirals during pregnancy.

Published
20 January 2015
From
CATIE
Poor weight gain during first year of ART associated with increased mortality risk for children with HIV in resource-limited settings

Poor weight gain after starting antiretroviral therapy (ART) is associated with increased mortality risk for children with HIV, investigators report in the online edition of AIDS. An international team

Published
09 December 2014
By
Michael Carter
Risk of birth defects small with HIV drugs

The risks of birth defects in children exposed to antiretroviral drugs in utero are small when considering the clear benefit of preventing mother-to-child transmission of HIV but where there are safe and effective alternatives, it might be appropriate to avoid use by pregnant women of drugs that may be associated with elevated risks of birth defects, such as zidovudine and efavirenz, according to a study published by French researchers published in this week's PLOS Medicine.

Published
30 April 2014
From
EurekAlert
HIV Drug Linked to Low Bone Density in Babies

In a cohort study, babies of mothers taking tenofovir (Viread) had an average whole-body bone mineral content about 8 grams less than babies whose mothers did not use the drug, according to George Siberry, MD, of the National Institute of Child Health and Human Development in Bethesda, Md

Published
07 March 2014
From
MedPage Today
Intrauterine, postnatal growth unaffected by exposure to HIV, antenatal antiretrovirals

Exposure to HIV and antenatal antiretrovirals did not significantly affect infants’ intrauterine or early postnatal growth, according to study results published in The Pediatric Infectious Disease Journal.

Published
08 January 2014
From
Healio
Improved caregiver training helps HIV-infected children

Children born with HIV can live longer and richer lives if their caregivers receive training in ways to enhance the children’s development, according to research led by Michigan State University.

Published
15 August 2013
From
Michigan State University (press release)
Anti-HIV drugs may protect against puberty delays in HIV-infected children

For children who have been HIV-infected since birth, current anti-HIV drug regimens may protect against the delays in puberty that had been seen in HIV-infected children taking older regimens, according to researchers funded by the National Institutes of Health.

Published
15 August 2013
From
National Institutes of Health (press release)
Anti-HIV drugs in pregnancy not linked to children's language delays

The combinations of anti-HIV drugs recommended for pregnant women do not appear in general to increase their children's risk for language delay, according to a study from a National Institutes of Health research network.

Published
19 July 2013
From
National Institutes of Health (press release)
← First123...4Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.